Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Withou

• Status: Completed
• Trial end date: 1969-12-31

Summary

To investigate the safety of a standard triple therapy regimen of delavirdine (DLV), zidovudine (ZDV), and lamivudine (3TC) following 14 days of experimental treatment with regimens of tipranavir (TPV) with and without ritonavir (RTV)

• Phase: Phase 2

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Delavirdine; Lamivudine; Ritonavir; Stavudine; Tipranavir; Zidovudine